ALS is a progressive neurological disease that attacks the nerves
High BMI, weight gain linked to lasting decrease in ALS risk
(HealthDay)—High body mass index (BMI) and weight gain are associated
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) — MediciNova,
Transplanted bone marrow endothelial progenitor cells delay ALS disease progression
Transplantation of human bone marrow-derived endothelial progenitor cells (EPCs) into
CDC: U.S. Prevalence of ALS Was 5.2 Per 100,000 in 2015
MONDAY, Nov. 26, 2018 — In 2015, the prevalence of
Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company